RecruitingNCT06241326
Immunotherapy for Hepatocellular Carcinoma
A Real-world Study of Immunotherapy-based Combination Therapies in Chinese Patients With Hepatocellular Carcinoma
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Enrollment
11,000 participants
Start Date
Mar 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study is an observational real-world research conducted on Chinese hepatocellular carcinoma (HCC) patients. Its primary objective is to evaluate the safety and efficacy of immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Aged after 18 years (18 is included).
- Hepatocellular carcinoma diagnosed by pathology or imaging.
- Patients assessed by researchers as potentially benefiting from receiving immunotherapy-based combination regimens.
- For participants who have previously received treatment according to this protocol, a comprehensive pre-treatment assessment is required, including demographic information, tumor history, medical history, and baseline imaging examinations.
- Patients voluntarily enroll in this study.
Exclusion Criteria2
- Pregnant or lactating women.
- Other conditions regimented at investigators' discretion.
Interventions
OTHERImmunotherapy-based Combination Therapies
immunotherapy-based combination therapies in Chinese HCC patients within the practical context of real-world conditions
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06241326
Related Trials
Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients
NCT056298451 location
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
NCT074754031 location
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
NCT060775911 location
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
NCT054683592 locations
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
NCT0552895214 locations